Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
11 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
SPAGNA
Comunidad Valenciana
VALENCIA
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
A multicenter, double-blind, randomized, placebo-controlled, phase III study of idasanutlin, an MDM2 antagonist, with cytarabine versus cytarabine plus placebo in patients with relapsed or refractory acute myeloid leukemia (AML) - ES (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML who are not Candidates for Intensive Chemotherapy - ES (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
FLUGAZA: A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients with newly diagnosed acute myeloid leukemia - ES (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
REALIB: Phase I-II trial, open and nonrandomized, to assess the role of Idelalisib in patients with acute lymphoblastic leukemia (ALL) relapsed or refractory to other treatments, and in elderly patients with ALL in which it is advised against the use of conventional therapies - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
QUIWI: A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type AML - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
LAMVYX: A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute myeloid leukemia - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPAGNA
Comunidad Valenciana
VALENCIA